Member Info for chester18

It would seem that reality is beginning to dawn. Bringing the realisation that on current data alone, Scancell is worth a lot more than this derisory SP.

SCIB1 + CPI's increase to an 82% success rate in a population of only 30% of patients, has the potential to deliver £10's of millions of revenues per annum.

We have a greater than 90% chance that iSCIB+ will produce that same increase of an 82% success rate in 100% of patients. What is that worth per annum ?

If fact what will that be worth to Merck ??

Chester.

Short term holders and traders just see short term profits. The AIM market is seen as the place to trade the news, positive or negative. It has no bearing on where Scancell are on their journey.

The SCIB1 + CPI's results give me confidence that Immunobody is now a valuable platform. When we have news that Modi1 + CPI's also has great synergy, Moditope will also be another extremely valuable platform.

Data = Deals ........ Maybe Milan has changed our 'potential deal' landscape.

Chester.

You have to ask, why would RENE do an enthusiastic RNS ( re- INVIVO results ) and then not attend / present at an Exosomes Industry focused conference. We're they ever listed as definite attendee ?

It can't be that their science somehow got derailed as they did that RNS at 7.00am on the 4th Sept the day before the conference.

It does feel like something is happening in the background and I'm hoping that what ever 'it' is, that it's a positive thing.

Chester.

Morning fellow investors,

The point I was making is about "what is a good return on Vulpes investment " for them.

If a bid arrived tomorrow ( I have just realised there are 1,049,000,000 shares in issue taking into account Redmiles CLN's for 2025 ) for £0.50 a share when there is still risk attached to achieving ultimate success.

Would they be tempted ?

Of course they would, that's a heck of payoff.

As always with any bio deal it is the data that will determine the final value. On positive data from iSCIB1+ and Modi1 + CPI's mid to late 2024 at least one Pharma Co will flinch.

Chester.

Vulpes have invested twice, once at 6p and again in the raise at 14p. They have probably invested roughly, around £12m.

So what is a good enough return on that investment seeing as it has tied their money up for 5 years. Also they are not receiving monthly interest payments as Redmile do on their CLN's.

50p a share : 113 million shares = £56.5M

Not a bad return, but would only be £400M for the whole of Scancell. If large pharma wait to long and both iSCIB1+ and Modi1 prove synergy with CPIs mid 2024 I would think a bid would have to be around £800M+, purely because of the size of the potential market, which is in the Billions annually.

I would imagined that Redmile will stay invested until that kind of bid arrives.

Chester.

Given yesterday's wild ride up from 10.1p todays share price looks very 'range bound'.

Does anyone else think it being held back ?

Chester.

What is exciting is that the data shows such a high improvement over CPI alone.

The owners of all Checkpoints will be taking note and wondering what other indications could Immunobody increase their revenues. A similar success rate from the proposed iSCIB1+ SCOPE Trial extension could start a bidding war........" which would be nice "......

Chester.

Morning C11

You have been proved to be correct on the update of the SCOPE Trial.

The official indication was that it would be Q4.

I'm not used to Scancell being ahead of their predictions 😃😃, this is the second occasion where their own timelines have been improved upon.

The other striking improvement is the positive nature of todays RNS and that it also projects that positivity towards future trial data of both SCIB1 + CPI and coming update on MODI1 + CPI.

A very good day for all investors in Scancell and not to bad for the 10% traders.

Chester.

If that late trade is a worked Buy then it does bode well for tomorrow's direction of travel.

It would be very nice to see an RNS in the morning. lets hope so anyway.

Chester.

I'm having a good day....

This rise is being backed up with decent size Buys so its either massive anticipation of the coming Poster reveals or ?

Chester.

Hi Dracula1

None of us know exactly where Scancell are on the road to success. What is absolutely clear is that the in recent RNS's we have seen a progressive upturn in positivity. From February's 'Encouraging' to 'Very Encouraging' and now 'Great Progress'.

The other indicators are the recent High profile appointment's ( I include our Chairman of 7.1/2 months ) and that the company now employs over 60 people.

Scancell are on the 'Cusp' of having meaningful and positive data. We just don't know how wide the 'Cusp' is....... 😄.

The language in describing how the trials are moving forwards says to me that this weeks release of new trial data and next months Vaccine Conference 'SCIB1' data will be very positive and welcome news.

If it plays out as I'm hoping it will the SP should get a lift. Some encouraging news on deals ( AvidiMab or GlyMabs ) would be the icing on the cake.

Chester.

Is this another 'tick up' in the positivity of language used to describe our current clinical trial results ......

CEO Lindy Durrant says :

"we continue to 'make great progress' in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1"

I like that part of the comment, "continue to make great progress", it is a clear indication that Modi / CPI is so far looking good and the SCOPE Trial is doing the business.

It could also mean that the resected tumour examinations are showing the kind of 'T' Cell penetration that is required to convince potential Pharma Partners.

Looking forwards to seeing the actual CICON posters.

Chester.

Greatland were never going to do an AXS listing while there are so many 'unknowns' about the companies future.

Get the Newmont ownership out of the way. See if they have any reasons not to continue with our Havieron Joint Venture, see the Decline reach the Gold, update the MRE, have a Decision to Mine rubber stamped and finally have the mining Feasibility Study released by Newmont.

Then do the AXS listing. That would seem like common sense to me.

Chester.

I wondered what had happened to Modi2 as there was no mention of it in the Business Update RNS in July.

It's great to know that the development of Modi2 is still on course.

Very positive and upbeat RNS on Modi1 plus GlyMabs and Modi2 back in the game.

It would also seem we will have to wait another month to be updated on SCIB1.

Chester.

Excellent post KonarA,

I would expect that Scancell are talking to the CPI approved Pharma's to bring about a Moditope/ CPi trial in Ovarian Cancer.

The recent RNS states that successful results in the current CPi + Modi1 in Head & Neck and Renal will be pivotol in getting that Ovarian Combo underway. ( in so many words ).

Chester.

Morning Ray

I agree, from the info we have so far is does look like Moditope is not a magic bullet as a Mono Therapy in extremely late stage patients.

It may be the perfect answer in patients that have been diagnosed much earlier.

The mouse models probably did not have the complex mutations that are in formed human tumours that have been stressed by Chemo and various other drugs.

I'm still of the opinion that we had to start at the wrong end of the spectrum to find patients willing to take a chance on something so new. The truth is probably, that it is the doctors that need to be convinced and that will take time to achieve.

CICON Milan will most certainly be more about the SCOPE trial.

Chester.

Cleanerworld and emptyend, thanks for your posts.

So our Abstract / Poster could be available by next Monday or Tuesday, unless it has been selected for a more important slot due to its content being sufficiently interesting in the opinion of the Conference Committee.

Hopefully what we have to say is deemed above the norm and is selected.

Could be an interesting week and we are given a clear idea of how well both trials are moving forward.

Fingers crossed.

Chester.

Checking the CICON program schedule I'm guessing that our Poster Presentation will be Friday 22nd poster session 'B' 12.45pm to 2.00pm.

Question for any that might know the answer :

Will that Poster be released to be viewed by RNS on the Friday morning ?

Chester.

Good post Debs

Only two weeks to wait for some of that potential SP moving news to arrive.

Followed very swiftly by the World Vaccine Conference and our year end accounts in late October.

Apart from those Macmillan revelations everything else Scancell wise seems to be heading in a positive direction.

Two weeks is a very short wait to hear about SCIB1 and MODI1.

Chester.

I really enjoy our in depth debates and logically thought through positions.

We are a very close family, with never an unkind word.

Chester.

Got to go, they're locking the doors and tuning off the lights soon ........ 🤫